<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493454</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0571</org_study_id>
    <nct_id>NCT00493454</nct_id>
  </id_info>
  <brief_title>Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas</brief_title>
  <official_title>Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  Overall Response Rate (ORR).

      Secondary Objectives:

        -  The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients
           and in the responders.

        -  Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses
           (PR).

        -  Time to next anticancer therapy (TTNT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ^90 Y Ibritumomab tiuxetan and rituximab are both designed to attach to lymphoma cells,
      causing them to die.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in this
      study. You will have a physical exam. Your blood (about 2 to 3 teaspoons) and urine will be
      collected for routine tests. You will have a chest x-ray and computerized tomography (CT)
      scans of the neck, chest, abdomen, and pelvis. You will have a bone marrow aspirate and
      biopsy performed. To collect a bone marrow aspirate and biopsy, an area of the hip or chest
      bone is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn
      through a large needle. Women who are able to have children must have a negative blood
      pregnancy test.

      The study doctors will first make sure that your disease has not spread too much and is not
      too severe to require immediate treatment with chemotherapy before you can begin treatment on
      this study. If you are found to be eligible to take part in this study, you will be given
      Benadryl (diphenhydramine) by vein, and you will be given Tylenol (acetaminophen) by mouth
      before each dose of rituximab. This is done to help decrease the risk of developing side
      effects of rituximab. You will then receive 1 dose of rituximab by vein over 6 to 8 hours on
      Day 1 of treatment. After treatment with rituximab, you will then be given a radioactive
      antibody, ^111 In Ibritumomab tiuxetan (this is a radioactive agent that binds to rituximab
      to help with imaging exams), by vein over about 10 minutes. This is so researchers can use a
      special camera to see where the drug is in your body.

      You will have imaging performed (with the special camera) on Day 1 and on either Day 2 or Day
      3. On Day 8, you will receive a second dose of rituximab. This will then be followed by a
      dose ^90 Y Ibritumomab tiuxetan of given by vein over 10 minutes. This completes the
      treatment.

      If you experience intolerable side effects while on this study, you may be removed from this
      study. The study doctor will then offer other treatment options to you.

      For your follow-up, you will have blood (about 2 tablespoons) drawn once a week for the first
      3 months, then every 3 months for 1 year, and then every 4 months for the second year. At
      these visits, you may also have CT scans, x-rays, and bone marrow biopsies and aspirates
      performed, if needed.

      This is an investigational study. ^90 Y Ibritumomab tiuxetan and rituximab have been approved
      by the FDA for the treatment of indolent B-cell lymphoma. Up to 35 patients will take part in
      this multicenter study. Up to 15 will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Evaluation 4 weeks after administration of Zevalin up to 3 years</time_frame>
    <description>Objective response rate (ORR) = number of participants out of all participating with Complete Response (CR) + Partial Response (PR) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. Response assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scans, every 3 months for the first year and every 6 months up to 3 years following.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibritumomab tiuxetan + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zevalin</intervention_name>
    <description>.3 mCi IV Over 10 Minutes x 1 Day</description>
    <arm_group_label>Ibritumomab tiuxetan + Rituximab</arm_group_label>
    <other_name>Ibritumomab Tiuxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>250 mg/m^2 IV Over 6 to 8 Hours</description>
    <arm_group_label>Ibritumomab tiuxetan + Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>^111 In Ibritumomab Tiuxetan</intervention_name>
    <description>1.6 mg IV Over 10 Minutes x 1 Day</description>
    <arm_group_label>Ibritumomab tiuxetan + Rituximab</arm_group_label>
    <other_name>Indium-111</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or
             Mitomycin C) prior to study initiation, and fully recovered from acute toxicities
             associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.

          2. Previously treated patients with a histology of refractory/relapsed indolent lymphomas
             including: (a) Extranodal marginal lymphoma of MALT type; (b) Nodal Marginal zone
             B-cell lymphoma (+/- monocytoid cells); (c) Splenic marginal B-cell lymphoma (+/-
             villous lymphocytes).

          3. Signed informed consent

          4. Age &gt;/= 18 years

          5. Expected survival &gt;/= 3 months

          6. Pre-study Zubrod performance status of 0, 1, or 2

          7. Acceptable hematologic status within two weeks prior to patient registration,
             including: (a) Absolute neutrophil count ([segmented neutrophils + bands] * total
             white blood count (WBC)) &gt;/= 1,500/mm^3; (b) Platelet counts &gt;/= 100,000/mm^3.

          8. Female patients who are not pregnant or lactating

          9. Men and women of reproductive potential who are following accepted birth control
             methods (as determined by the treating physician)

         10. Patients previously on Phase II drugs if no long-term toxicity is expected, and the
             patient has been off the drug for eight or more weeks with no significant post
             treatment toxicities observed

         11. Patients determined to have &lt; 25% bone marrow involvement with lymphoma within six
             weeks of registration (define measurement of a bone marrow aspirate or biopsy) (This
             criteria must be strictly met for adequate patient safety.)

         12. Patient should have at least one lesion measuring &gt;/= 2 cm in a single dimension.

        Exclusion Criteria:

          1. Prior myeloablative therapies with autologous bone marrow transplantation (ABMT) or
             peripheral blood stem cell (PBSC) rescue.

          2. Platelet count&lt; 100,000 cells/mm^3.

          3. Presence of hypocellular bone marrow.

          4. Patients with history of failed stem cell collection.

          5. Prior radioimmunotherapy

          6. Presence of Central Nervous System (CNS) lymphoma

          7. Patients with HIV.

          8. Patients with pleural effusion

          9. Patients with abnormal liver function: total bilirubin &gt; 2.0 mg/dL

         10. Patients with abnormal renal function: serum creatinine &gt; 2.0 mg/dL

         11. Patients who have received prior external beam radiation therapy to &gt; 25% of active
             bone marrow (involved field or regional)

         12. Patients who have received short-acting growth factor support (Leukine, Neupogen,
             Procrit) within 2 weeks prior to treatment or long-acting growth-factor support
             (Aranesp), Neulasta) within 4 weeks prior to treatment.

         13. Serious nonmalignant disease or infection which, in the opinion of the investigator
             and/or the sponsor, would compromise other protocol objectives

         14. Major surgery, other than diagnostic surgery, within four weeks

         15. Evidence of transformation in the latest biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Samaniego, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center Official Web Site</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <results_first_submitted>September 28, 2012</results_first_submitted>
  <results_first_submitted_qc>May 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 31, 2013</results_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indolent Lymphoma</keyword>
  <keyword>Extranodal Marginal</keyword>
  <keyword>Nodal Marginal Zone</keyword>
  <keyword>Splenic Marginal</keyword>
  <keyword>MALT Type</keyword>
  <keyword>Zevalin</keyword>
  <keyword>Ibritumomab Tiuxetan</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: April 13, 2006 to November 8, 2007. All participants recruited in medical clinic at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibritumomab Tiuxetan + Rituximab</title>
          <description>Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibritumomab Tiuxetan + Rituximab</title>
          <description>Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" lower_limit="55" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>Objective response rate (ORR) = number of participants out of all participating with Complete Response (CR) + Partial Response (PR) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. Response assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scans, every 3 months for the first year and every 6 months up to 3 years following.</description>
        <time_frame>Evaluation 4 weeks after administration of Zevalin up to 3 years</time_frame>
        <population>One participant did not receive treatment and was excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibritumomab Tiuxetan + Rituximab</title>
            <description>Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective response rate (ORR) = number of participants out of all participating with Complete Response (CR) + Partial Response (PR) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. Response assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scans, every 3 months for the first year and every 6 months up to 3 years following.</description>
          <population>One participant did not receive treatment and was excluded from analysis.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibritumomab Tiuxetan + Rituximab</title>
          <description>Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Felipe Samaniego, MD / Associate Professor</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

